Present and Future of Personalised Medicine for Endocrine Cancers
Major technological advances in genomics have made it possible to identify critical genetic alterations in cancer, rendering oncology well along the path to “personalised cancer medicine”. Thanks to developments in genetics, several mutations and gene rearrangements have been identified in patients...
Uloženo v:
| Médium: | Online |
|---|---|
| Jazyk: | angličtina |
| Vydáno: |
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
| Témata: | |
| On-line přístup: | ONIX_20220621_9783036543307_91 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| _version_ | 1869527699158990848 |
|---|---|
| collection | Directory of Open Access Books |
| description | Major technological advances in genomics have made it possible to identify critical genetic alterations in cancer, rendering oncology well along the path to “personalised cancer medicine”. Thanks to developments in genetics, several mutations and gene rearrangements have been identified in patients with endocrine cancers (e.g., thyroid and adrenocortical carcinoma). In particular, each patient can be considered as a unique, individual one, with unique genetic information. The aim of this Special Issue is to offer an overview of exciting new research in the area of endocrine tumours may set the stage for an innovative personalised management and precision medicine modalities for individualised care.New affordable individual genomic analyses, as well as the opportunity to test new compounds in primary cells may allow a personalised management of patients with endocrine malignancies. This approach may improve the prediction of clinical outcome and therapeutic effectiveness, as well as help to avoid the use of ineffective drugs. However, further efforts are needed to obtain an adjustment of clinical management in patients with endocrine cancers that would rely solely or in great part on genetic information. This Special Issue includes basic, translational, and clinical papers on personalised medicine in endocrine malignancies (i.e., thyroid and adrenal), especially focusing on diagnostic and prognostic biomarkers, as well as novel drug targets or targeted treatments, including eventual clinical trials. |
| format | Online |
| id | doab-20.500.12854ir-84513 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2022 |
| publishDateRange | 2022 |
| publishDateSort | 2022 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-845132024-03-31T13:09:54Z Present and Future of Personalised Medicine for Endocrine Cancers Ronchi, Cristina L. Altieri, Barbara papillary thyroid cancer SUV PET/CT BRAF V600E immune checkpoint inhibitors (ICIs) ipilimumab nivolumab prolactinoma Cushing’s disease aggressive pituitary tumor aggressive PitNET aggressive pituitary adenoma pituitary carcinoma adrenocortical cancer adrenal adenomas adrenal tumors p53 p27 ki-67 reticulin mitotane adjuvant treatment recurrence recurrence free survival timing intratumoral heterogeneity thyroid tumor BRAF RET/PTC rearrangements RAS mutation adrenal cortex carcinoma angiogenesis gene expression osteopontin hyaluronan synthase 1 multikinase inhibitors sorafenib lenvatinib differentiated thyroid cancer radioiodine resistance predictive marker predictors response to treatment survival information needs and preferences focus group interview personalized medicine neuroendocrine tumours phaeochromocytoma paraganglioma molecular clusters n/a thema EDItEUR::M Medicine and Nursing Major technological advances in genomics have made it possible to identify critical genetic alterations in cancer, rendering oncology well along the path to “personalised cancer medicine”. Thanks to developments in genetics, several mutations and gene rearrangements have been identified in patients with endocrine cancers (e.g., thyroid and adrenocortical carcinoma). In particular, each patient can be considered as a unique, individual one, with unique genetic information. The aim of this Special Issue is to offer an overview of exciting new research in the area of endocrine tumours may set the stage for an innovative personalised management and precision medicine modalities for individualised care.New affordable individual genomic analyses, as well as the opportunity to test new compounds in primary cells may allow a personalised management of patients with endocrine malignancies. This approach may improve the prediction of clinical outcome and therapeutic effectiveness, as well as help to avoid the use of ineffective drugs. However, further efforts are needed to obtain an adjustment of clinical management in patients with endocrine cancers that would rely solely or in great part on genetic information. This Special Issue includes basic, translational, and clinical papers on personalised medicine in endocrine malignancies (i.e., thyroid and adrenal), especially focusing on diagnostic and prognostic biomarkers, as well as novel drug targets or targeted treatments, including eventual clinical trials. 2022-06-21T08:39:27Z 2022-06-21T08:39:27Z 2022 book ONIX_20220621_9783036543307_91 9783036543307 9783036543291 https://directory.doabooks.org/handle/20.500.12854/84513 eng application/octet-stream Attribution 4.0 International https://mdpi.com/books/pdfview/book/5497 https://mdpi.com/books/pdfview/book/5497 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-4329-1 10.3390/books978-3-0365-4329-1 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036543307 9783036543291 140 Basel open access |
| spellingShingle | papillary thyroid cancer SUV PET/CT BRAF V600E immune checkpoint inhibitors (ICIs) ipilimumab nivolumab prolactinoma Cushing’s disease aggressive pituitary tumor aggressive PitNET aggressive pituitary adenoma pituitary carcinoma adrenocortical cancer adrenal adenomas adrenal tumors p53 p27 ki-67 reticulin mitotane adjuvant treatment recurrence recurrence free survival timing intratumoral heterogeneity thyroid tumor BRAF RET/PTC rearrangements RAS mutation adrenal cortex carcinoma angiogenesis gene expression osteopontin hyaluronan synthase 1 multikinase inhibitors sorafenib lenvatinib differentiated thyroid cancer radioiodine resistance predictive marker predictors response to treatment survival information needs and preferences focus group interview personalized medicine neuroendocrine tumours phaeochromocytoma paraganglioma molecular clusters n/a thema EDItEUR::M Medicine and Nursing Present and Future of Personalised Medicine for Endocrine Cancers |
| title | Present and Future of Personalised Medicine for Endocrine Cancers |
| title_full | Present and Future of Personalised Medicine for Endocrine Cancers |
| title_fullStr | Present and Future of Personalised Medicine for Endocrine Cancers |
| title_full_unstemmed | Present and Future of Personalised Medicine for Endocrine Cancers |
| title_short | Present and Future of Personalised Medicine for Endocrine Cancers |
| title_sort | present and future of personalised medicine for endocrine cancers |
| topic | papillary thyroid cancer SUV PET/CT BRAF V600E immune checkpoint inhibitors (ICIs) ipilimumab nivolumab prolactinoma Cushing’s disease aggressive pituitary tumor aggressive PitNET aggressive pituitary adenoma pituitary carcinoma adrenocortical cancer adrenal adenomas adrenal tumors p53 p27 ki-67 reticulin mitotane adjuvant treatment recurrence recurrence free survival timing intratumoral heterogeneity thyroid tumor BRAF RET/PTC rearrangements RAS mutation adrenal cortex carcinoma angiogenesis gene expression osteopontin hyaluronan synthase 1 multikinase inhibitors sorafenib lenvatinib differentiated thyroid cancer radioiodine resistance predictive marker predictors response to treatment survival information needs and preferences focus group interview personalized medicine neuroendocrine tumours phaeochromocytoma paraganglioma molecular clusters n/a thema EDItEUR::M Medicine and Nursing |
| topic_facet | papillary thyroid cancer SUV PET/CT BRAF V600E immune checkpoint inhibitors (ICIs) ipilimumab nivolumab prolactinoma Cushing’s disease aggressive pituitary tumor aggressive PitNET aggressive pituitary adenoma pituitary carcinoma adrenocortical cancer adrenal adenomas adrenal tumors p53 p27 ki-67 reticulin mitotane adjuvant treatment recurrence recurrence free survival timing intratumoral heterogeneity thyroid tumor BRAF RET/PTC rearrangements RAS mutation adrenal cortex carcinoma angiogenesis gene expression osteopontin hyaluronan synthase 1 multikinase inhibitors sorafenib lenvatinib differentiated thyroid cancer radioiodine resistance predictive marker predictors response to treatment survival information needs and preferences focus group interview personalized medicine neuroendocrine tumours phaeochromocytoma paraganglioma molecular clusters n/a thema EDItEUR::M Medicine and Nursing |
| url | ONIX_20220621_9783036543307_91 |